Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 26 Top line growth driven by the diabetes pandemic Novo Nordisk reported quarterly sales International Diabetes Federation projects that 642 million people will have diabetes by 2040 by therapy Diabetes and obesity DKK billion 35 30 Haemophilia² NorditropinⓇ Other Million USA Region China people 700 Reported sales CAGR¹: 11.1% 600 CAGR¹: 7.0% 225 7.7% 20 9.3% 15 5.1% 10 12.4% 500 415 400 300 200 151 5 100 Europe Pacific International Operations 642 0 Q3 2006 Q3 2016 2000 2015 2040E 1 CAGR for 10-year period Note: 20-79 age group 2 Haemophilia includes NovoSeven®, NovoThirteenⓇ (as of Q1 2013) and NovoEight® (as of Q1 2014) 1 CAGR for 15-year period Source: International Diabetes Federation: Diabetes Atlas 1st and 7th Edition, 2000 and 2015 changing diabetes® novo nordisk

View entire presentation